ライフサイエンスコーパス: vulvovaginal

1 Information about vulvovaginal and perianal condylomata acuminata and intr

2 Vulvovaginal and perianal condylomata acuminata or intra

3 The treatment of vulvovaginal atrophy includes administration of estrogen

4 n, uniformly had clinical evidence of severe vulvovaginal atrophy, dyspareunia (median pain score, 8

5 promising as a therapeutic option to improve vulvovaginal atrophy.

6 ), gonorrhea (HR, 1.6; 95% CI, 1.1-2.2), and vulvovaginal candidiasis (HR, 1.5; 95% CI, 1.3-1.8).

7 Studies from women with recurrent vulvovaginal candidiasis (RVVC) and from an animal model

8 not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women.

9 e and susceptibility to recurrent idiopathic vulvovaginal candidiasis (RVVC) was investigated.

10 Vulvovaginal candidiasis (VVC) caused by Candida albican

11 Vulvovaginal candidiasis (VVC) caused by Candida albican

12 Vulvovaginal candidiasis (VVC) caused by the commensal o

13 sseminated candidiasis (HDC) and episodes of vulvovaginal candidiasis (VVC) in humans, we found evide

14 Vulvovaginal candidiasis (VVC) is a common mucosal infec

15 Vulvovaginal candidiasis (VVC) is a high-incidence disea

16 Vulvovaginal candidiasis (VVC) is an insidious infection

17 Vulvovaginal candidiasis (VVC) is an opportunistic mucos

18 Candida test using a reference standard for vulvovaginal candidiasis (VVC) of yeast culture plus exc

19 Acute and recurrent vulvovaginal candidiasis (VVC) remains a significant pro

20 s the causative agent of acute and recurrent vulvovaginal candidiasis (VVC), a common mucosal infecti

21 rial vaginosis (BV), 25 acquired symptomatic vulvovaginal candidiasis (VVC), and 7 acquired vaginal t

22 ion with lactobacilli may reduce the risk of vulvovaginal candidiasis (VVC), but supporting data are

23 Vulvovaginal candidiasis (VVC), caused by Candida albica

24 Vulvovaginal candidiasis (VVC), caused by Candida specie

25 opharyngeal candidiasis (OPC), as opposed to vulvovaginal candidiasis (VVC), is a common opportunisti

26 ections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or Trichomonas vaginalis

27 ctions, notably bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), particularly in the sett

28 = 2) with OPC in 1 patient, whereas isolated vulvovaginal candidiasis (VVC; n = 3) was not.

29 anslocation, nor do we implicate the gene in vulvovaginal candidiasis among mice in pseudoestrus.

30 oth clinical studies of women with recurrent vulvovaginal candidiasis and a murine model of experimen

31 24 premenopausal women with acute recurrent vulvovaginal candidiasis and from 21 healthy asymptomati

32 In contrast, vulvovaginal candidiasis has a much weaker association w

33 The risks of GUD and vulvovaginal candidiasis increased with progressive leve

34 women with non-antibiotic-induced recurrent vulvovaginal candidiasis suffering from acute Candida va

35 e randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluco

36 b-), the relative risk of chronic recurring vulvovaginal candidiasis was 2.41-4.39, depending on the

37 infection, Trichomonas vaginalis infection, vulvovaginal candidiasis, and bacterial vaginosis) in HI

38 Vulvovaginal candidiasis, caused primarily by Candida al

39 chlamydia, bacterial vaginosis, trichomonas, vulvovaginal candidiasis, pelvic inflammatory disease, g

40 e antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely perf

41 ypeptides in both bacterial vaginosis and in vulvovaginal candidiasis, suggesting that the abnormalit

42 Unlike in vulvovaginal candidiasis, the neutrophil attractant chem

43 o colonization and immunopathogenesis during vulvovaginal candidiasis.

44 protection in oral infection but exacerbate vulvovaginal candidiasis.

45 ed to fluid from healthy women or women with vulvovaginal candidiasis.

46 March 2001 from 429 patients with suspected vulvovaginal candidiasis.

47 reduce the rate of recurrence of symptomatic vulvovaginal candidiasis.

48 zole was effective in preventing symptomatic vulvovaginal candidiasis.

49 be effective for the management of recurrent vulvovaginal candidiasis.

50 Despite therapeutic advances, vulvovaginal candidosis remains a common problem worldwi

51 in both overdiagnosis and underdiagnosis of vulvovaginal candidosis.

52 that presented as the oral component of the vulvovaginal-gingival syndrome.

53 s appears to reduce the risk of cervical and vulvovaginal HPV infection.

54 patients with recurrent infections, oral and vulvovaginal isolates were identical, in 35% they were h

55 o (1%) of 341 HIV-1-negative women developed vulvovaginal or perianal lesions, resulting in an incide

56 We investigated vaginal size, vulvovaginal pathology and the presence of the main huma

57 ltaneously cultured from the oral cavity and vulvovaginal region of healthy individuals.

58 Cervical and vulvovaginal samples for HPV DNA testing and Papanicolao

59 questionnaire was completed and cervical and vulvovaginal samples were collected to detect HPV DNA.

60 necologic examinations included cervical and vulvovaginal specimen collection for Pap and HPV DNA tes

61 rtner was identical or highly related to the vulvovaginal strain.

62 that included HPV genotyping of cervical and vulvovaginal swab specimens and collection of colposcopy

63 In community settings, both vulvovaginal-swab and first-catch urine specimens from w

64 ting Chlamydia trachomatis in self-collected vulvovaginal-swab and first-catch urine specimens from w

65 We tested 2,745 paired vulvovaginal-swab and urine specimens by PCR (Roche Coba

66 I], 93.1 to 99.2%) of infected patients with vulvovaginal-swab specimens and 91.8% (86.1 to 95.7%) wi

67 We tested 2,749 vulvovaginal-swab specimens with both a nucleic acid amp

68 tivity of an amplified enzyme immunoassay on vulvovaginal-swab specimens.

69 and behavioral information and cervical and vulvovaginal swabs for HPV DNA assay were obtained at 4-

70 musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients